RWP
REGN icon

RWA Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

RWA Wealth Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$308K Sell
398
-2
-0.5% -$1.53K ﹤0.01% 532
2025
Q4 		$309K Sell
400
-6,204
-94% -$4.21M ﹤0.01% 518
2025
Q3 		$3.71M Sell
6,604
-994
-13% -$562K 0.04% 202
2025
Q2 		$3.99M Sell
7,598
-10,372
-58% -$5.79M 0.05% 179
2025
Q1 		$11.4M Sell
17,970
-456
-2% -$314K 0.14% 90
2024
Q4 		$13.1M Buy
18,426
+18,027
+4,518% +$15.1M 0.16% 85
2024
Q3 		$419K Buy
399
+2
+0.5% +$2.23K 0.01% 423
2024
Q2 		$417K Hold
397
– – 0.01% 411
2024
Q1 		$382K Sell
397
-30
-7% -$28.5K 0.01% 425
2023
Q4 		$375K Buy
+427
New +$352K 0.01% 412
2020
Q2 		– Sell
-998
Closed -$487K – 219
2020
Q1 		$487K Sell
998
-26
-3% -$10.7K 0.07% 134
2019
Q4 		$384K Sell
1,024
-15
-1% -$5.05K 0.04% 183
2019
Q3 		$288K Sell
1,039
-10
-1% -$2.96K 0.03% 201
2019
Q2 		$328K Hold
1,049
– – 0.04% 181
2019
Q1 		$431K Sell
1,049
-56
-5% -$23.1K 0.05% 166
2018
Q4 		$413K Hold
1,105
– – 0.05% 156
2018
Q3 		$446K Hold
1,105
– – 0.05% 154
2018
Q2 		$381K Buy
+1,105
New +$346K 0.04% 174

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

RWA Wealth Partners's REGN Position: Q1 2026 in Review

RWA Wealth Partners reduced its Regeneron Pharmaceuticals (REGN) stake by 0.5% in Q1 2026, selling an estimated $1.53K and leaving 398 shares worth $308K. The position accounts for ﹤0.01% of the portfolio, ranked #532.

RWA Wealth Partners first reported a position in REGN in Q2 2018 and has held it in 18 quarters since. The position peaked at $13.1M in Q4 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • RWA Wealth Partners held 398 shares of Regeneron Pharmaceuticals worth $308K as of Q1 2026.
  • RWA Wealth Partners sold 2 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $1.53K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of RWA Wealth Partners's portfolio in Q1 2026, its #532 holding.
  • RWA Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q2 2018 and has held it in 18 quarters since.
  • RWA Wealth Partners's Regeneron Pharmaceuticals position peaked at $13.1M in Q4 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on RWA Wealth Partners's 13F filing for Q1 2026, filed 13 May 2026.